Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$6.33
-6.9%
$5.36
$2.69
$7.01
$501.15M0.89348,356 shs331,877 shs
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$6.16
-4.8%
$6.80
$5.75
$14.50
$295.06MN/A138,013 shs114,518 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$6.47
-1.2%
$10.98
$3.91
$18.15
$186.14M1.8105,326 shs64,420 shs
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
$12.03
-1.2%
$13.95
$9.69
$26.11
$285.83M1.24296,171 shs184,769 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
-6.91%-5.38%+25.60%+17.22%+124.47%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-4.79%-8.61%+1.65%-26.05%+615,999,900.00%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-1.22%-6.37%-48.65%-54.50%+54.05%
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
-1.23%-5.50%-13.14%-23.57%-50.17%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
3.6712 of 5 stars
3.50.00.00.03.34.21.9
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
3.0201 of 5 stars
3.43.00.00.03.04.20.6
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
3.0958 of 5 stars
3.51.00.00.01.72.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
3.00
Buy$8.0026.38% Upside
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
3.00
Buy$22.00257.14% Upside
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.86
Moderate Buy$15.67142.14% Upside
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
3.00
Buy$30.00149.38% Upside

Current Analyst Ratings

Latest TCMD, BVS, NPCE, and GUTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$18.00
5/8/2024
Bioventus Inc. stock logo
BVS
Bioventus
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
3/14/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
3/13/2024
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $9.00
(Data available from 6/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$512.34M0.98$0.74 per share8.60$2.80 per share2.26
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$120K2,458.87N/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$65.42M2.85N/AN/A$0.79 per share8.19
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
$274.42M1.04$1.52 per share7.94$8.24 per share1.46

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$0.35N/A14.72N/A-4.14%11.91%3.29%8/13/2024 (Estimated)
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$77.09MN/A0.00N/AN/AN/AN/AN/A8/12/2024 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$32.96M-$1.19N/AN/AN/A-45.61%-173.62%-30.89%8/13/2024 (Estimated)
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
$28.51M$1.2010.0314.85N/A10.19%15.88%10.33%8/5/2024 (Estimated)

Latest TCMD, BVS, NPCE, and GUTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024Q1 2024
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$0.30-$0.75-$0.45-$1.33N/A$0.03 million
5/8/2024Q1 2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.32-$0.32N/A-$0.32$18.12 million$18.12 million
5/7/2024Q1 2024
Bioventus Inc. stock logo
BVS
Bioventus
-$0.05$0.07+$0.12$0.21$115.51 million$129.46 million
5/6/2024Q1 2024
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
-$0.11-$0.05+$0.06-$0.01$59.10 million$61.09 million
4/1/2024Q4 2023
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/A-$8.02-$8.02-$4.86N/A$0.01 million
3/12/2024Q4 2023
Bioventus Inc. stock logo
BVS
Bioventus
$0.06$0.07+$0.01$0.24$124.84 million$135.42 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.63
1.53
0.97
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
0.34
9.38
9.37
NeuroPace, Inc. stock logo
NPCE
NeuroPace
4.05
6.43
5.56
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
0.13
4.26
3.63

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
83.43%

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
32.90%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
22.20%
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
0.96%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
99579.17 million53.12 millionNot Optionable
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
10247.90 millionN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17128.77 million22.38 millionOptionable
Tactile Systems Technology, Inc. stock logo
TCMD
Tactile Systems Technology
99223.76 million23.53 millionOptionable

TCMD, BVS, NPCE, and GUTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bioventus logo

Bioventus

NYSE:BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Fractyl Health logo

Fractyl Health

NASDAQ:GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
NeuroPace logo

NeuroPace

NASDAQ:NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Tactile Systems Technology logo

Tactile Systems Technology

NASDAQ:TCMD
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.